Triangle Securities Wealth Management Acquires 1,440 Shares of Danaher Co. (NYSE:DHR)

Triangle Securities Wealth Management raised its stake in shares of Danaher Co. (NYSE:DHR) by 62.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 3,746 shares of the conglomerate’s stock after purchasing an additional 1,440 shares during the quarter. Triangle Securities Wealth Management’s holdings in Danaher were worth $860,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Decker Retirement Planning Inc. purchased a new stake in Danaher in the fourth quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Danaher during the 3rd quarter valued at $39,000. MidAtlantic Capital Management Inc. purchased a new position in shares of Danaher in the 3rd quarter worth $40,000. FSA Wealth Management LLC bought a new stake in shares of Danaher in the third quarter worth $50,000. Finally, Darwin Wealth Management LLC purchased a new stake in Danaher during the third quarter valued at $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 1.4 %

Shares of NYSE DHR opened at $238.41 on Friday. The stock has a market capitalization of $172.20 billion, a P/E ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83. Danaher Co. has a 1-year low of $222.53 and a 1-year high of $281.70. The business’s 50 day moving average is $234.85 and its two-hundred day moving average is $253.32. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.02 EPS. As a group, research analysts expect that Danaher Co. will post 7.49 EPS for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s dividend payout ratio is presently 20.61%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on DHR shares. Stephens restated an “overweight” rating and set a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. KeyCorp boosted their target price on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Barclays decreased their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Finally, Royal Bank of Canada decreased their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average price target of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.